Z6×ðÁú

¡°ÊØÎÀÉö¹¦Ð§¡ªIgAÉöÓѰٳǹ«ÒæÐС±³¤É³Õ¾ÔÚZ6×ðÁú´óÒ©·¿ÎåÒ»ÆðµêÀֳɾÙÐÐ

Ê×Ò³|Z6×ðÁúÖйú¹Ù·½ÍøÕ¾
IgAÉö²¡ÊÇÈ«Çò¹æÄ£ÄÚ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡Ö®Ò»£¬£¬£¬£¬ £¬£¬£¬ÔÚÎÒ¹ú¼°¶«Ñǹú¼ÒÓÈΪ³£¼û¡£¡£ ¡£¡£¡£´ó´ó¶¼»¼ÕßÌåÏÖΪÉöÔಡ»ºÂýÏ£Íû£¬£¬£¬£¬ £¬£¬£¬Êǵ¼ÖÂÇàÄêÈËÖÕδÆÚÉö²¡µÄ×î³£¼û²¡Òò£¬£¬£¬£¬ £¬£¬£¬¸ø¼ÒÍ¥ºÍÉç»á´øÀ´Á˼«Öصļ²²¡¼ç¸º¡¾1¡¿¡£¡£ ¡£¡£¡£ÔÚIgAÉö²¡µÄÖÎÁÆÀú³ÌÖУ¬£¬£¬£¬ £¬£¬£¬»¼Õß½ÌÓýÊÇÖ÷Òª»·½Ú£¬£¬£¬£¬ £¬£¬£¬¶øÏÖÔÚIgAÉö²¡»¼Õߵļ²²¡ÈÏÖª¡¢×ÔÎÒ¹ÜÀíÄÜÁ¦ÈÔÓнϴóÌáÉý¿Õ¼äºÍδ֪×ãÐèÇ󡣡£ ¡£¡£¡£
ΪÁË×ÊÖú¸ü¶àIgAÉö²¡»¼Õß»ñÈ¡ÕïÁÆÖªÊ¶¡¢Ìá¸ß¼²²¡¹ÜÀíÄÜÁ¦£¬£¬£¬£¬ £¬£¬£¬¡°ÊØÎÀÉö¹¦Ð§¡ªIgAÉöÓѰٳǹ«ÒæÐС±ÏîÄ¿³¤É³Õ¾Ô˶¯ÔÚZ6×ðÁú´óÒ©·¿ÎåÒ»Æðµê¾ÙÐУ¬£¬£¬£¬ £¬£¬£¬Í¨¹ýÏßÉÏÏßÏÂÏàÍŽáµÄÉöÓѽÌÓýÔ˶¯¡¢Ò½»¼»¥¶¯¼°¿ÆÆÕÈö²¥£¬£¬£¬£¬ £¬£¬£¬Íƶ¯»¼ÕßÔçÕïÔçÖΣ¬£¬£¬£¬ £¬£¬£¬´Ó¶øÑÓ»º¼²²¡Ï£Íû£¬£¬£¬£¬ £¬£¬£¬Ìá¸ßÉúÑÄÖÊÁ¿¡£¡£ ¡£¡£¡£
Ê×Ò³|Z6×ðÁúÖйú¹Ù·½ÍøÕ¾
³¤É³ÊÐÉö´È¹«Òæ·þÎñÖÐÐÄÀíʳ¤ºî¼ÑÏÖ³¡Ö´ǣ¬£¬£¬£¬ £¬£¬£¬·ÖÏí¹«ÒæÁ¦Á¿ÔÚÉö²¡Ôçɸ¡¢»¼Õß½ÌÓý¼°ÐÄÀíÖ§³ÖµÈ·½ÃæµÄʵ¼ùÂÄÀú¡£¡£ ¡£¡£¡£
±¾´ÎÔ˶¯Ô¼ÇëÁËÖÐÄÏ´óÑ§ÏæÑÅÈýÒ½ÔºÉöÄÚ¿ÆÁõ¼Íʵ½ÌÊÚ´øÀ´Ö÷Ìâ½²×ù£¬£¬£¬£¬ £¬£¬£¬ÒÔÕæÊµ°¸Àý½â˵IgAÉö²¡µÄ·¢²¡ÌåÏÖ¡¢ÉúÑÄÒûʳԭÔò¡¢IgAÉö²¡Ò©ÎïÕïÁƼƻ®µÈ֪ʶ£¬£¬£¬£¬ £¬£¬£¬ÃãÀø¸÷ÈË׼ȷÊìϤ¼²²¡£¡£ ¡£¡£¡£¬£¬£¬£¬ £¬£¬£¬×öµ½ÔçÕï¡¢ÔçÖΡ¢Ô綨ÐÄ¡£¡£ ¡£¡£¡£
Ê×Ò³|Z6×ðÁúÖйú¹Ù·½ÍøÕ¾
ÔÚÏÖ³¡´ðÒÉ»·½Ú£¬£¬£¬£¬ £¬£¬£¬Áõ¼Íʵ½ÌÊÚÕë¶Ô»¼ÕßÌåÌùµÄÎÊÌâÖðÒ»½â´ð¡£¡£ ¡£¡£¡£¹ØÓÚÐí¶àÉöÓÑÌåÌùµÄ²¼µØÄ峦ÈܽºÄÒµÄÎÊÌ⣬£¬£¬£¬ £¬£¬£¬Áõ½ÌÊÚ½â´ð£º²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÊÇÈ«ÇòÊ׸ö°ÐÏòIgAÉö²¡Ô´Í·–³¦µÀð¤Ä¤ÃâÒߵĶÔÒòÖÎÁÆÐÂÒ©£¬£¬£¬£¬ £¬£¬£¬ÊÇÊ׸öͬʱ±»ÃÀ¹úFDA¡¢Å·ÖÞEMA¡¢ÖйúNMPAÈý´óȨÍþÒ©¼à»ú¹¹Åú×¼ÓÃÓÚÖÎÁÆIgAÉö²¡µÄÁ¢ÒìÒ©Î2-7¡¿£¬£¬£¬£¬ £¬£¬£¬¾ßÓÐÖØ´óÁÙ´²ÒâÒå¡£¡£ ¡£¡£¡£ËüÊÊÓÃÓÚ¾ßÓÐÏ£ÍûΣº¦µÄÔ­·¢ÐÔIgAÉö²¡³ÉÄ껼Õߣ¬£¬£¬£¬ £¬£¬£¬¿ÉÒÔïÔÌ­Éö¹¦Ð§Ëðʧ£¬£¬£¬£¬ £¬£¬£¬Í¬Ê±½µµÍÂѰ×Äò¡¢¸ÄÉÆÑªÄò¡£¡£ ¡£¡£¡£
²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÔÚZ6×ðÁú´óÒ©·¿ÓÐÊÛ£¬£¬£¬£¬ £¬£¬£¬ÎÒÃÇÆð¾¢ÅäºÏÁÙ´²ÐèÇ󣬣¬£¬£¬ £¬£¬£¬ÊµÊ±ÎÈÍ׵ؽ«Ò©Æ·ÅäË͵½»¼ÕßÐèÒªµÄµØ·½¡£¡£ ¡£¡£¡£
Z6×ðÁú²¿·ÖDTPÒ©·¿ÐÅÏ¢Ò»ÀÀ£º
Ê×Ò³|Z6×ðÁúÖйú¹Ù·½ÍøÕ¾
²Î¿¼ÎÄÏ×£º

1.ÐÂÒ©Ó¦ÓúÍÖÎÁÆÕ½ÂÔת±äÓÐÍû¸ÄÉÆIgAÉö²¡»¼ÕßµÄÔ¤ºó[J]. ÖлªÒ½Ñ§ÐÅÏ¢µ¼±¨,2024,39(16):11. DOI:10.3760/cma.j.issn.1000-8039.2024.16.118.
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
ÉÏһƪÎÄÕÂ
Z6×ðÁúÖØ°õÐÂÆ·ÁÁÏà¹ãÖÝÒ©½»»á£¬£¬£¬£¬ £¬£¬£¬ÏÖ³¡Ç©Ô¼¿ªÍغ£ÄÚÍâÊг¡
ÏÂһƪÎÄÕÂ
¿ÆÑ§°ÍÊ¿¿ª½øZ6×ðÁú£¬£¬£¬£¬ £¬£¬£¬´ò¿¨ÖÐÒ½Ò©¿Æ¼¼ÎÄ»¯ºþÄÏÊ¡¿ÆÆÕ»ùµØ
ÍøÕ¾µØÍ¼